Cerenion

Cerenion operates at the intersection of medical devices, quantitative EEG, clinical software and neuroscience. Its differentiation is not simply an algorithm: the C-Trend proposition combines an electrode array, amplifier, medical PC, mobile cart and software intended to make continuous EEG accessible to clinicians who are not EEG specialists. The platform converts raw EEG into interpretable indicators including slow-wave activity, burst-suppression ratio, aEEG and alpha-delta ratio, targeting time-sensitive settings such as intensive care, emergency medicine, sedation monitoring and post-cardiac-arrest care. This integrated hardware-software model distinguishes Cerenion from narrower analytics vendors, while its acute-care focus separates it from general-purpose consumer neurotechnology products. Cerenion’s market challenge is therefore best framed around adoption and clinical workflow: hospitals must trust automated outputs, integrate them into existing EEG and monitoring processes, and satisfy medical-device and regulatory requirements.

Cerenion has followed a staged financing path since its 2017 founding. It raised a €500,000 seed round on Feb 5, 2018, a further €2 million seed round on Sep 12, 2019, and a €3.3 million Series A on Apr 12, 2022. The structured funding total for those three rounds is $6.4022 million. Additional signals point to financing and organizational development after that period: a €321,000 grant was dated Jun 1, 2024, and a €4.359 million share issue was dated May 28, 2026. Because the latter amounts are recorded in euros without corresponding USD values, they are not added to the prioritized USD total. The 2025 appointment of Product Manager Terhimaria Kaski is an operational inflection point, suggesting increasing attention to product execution and clinical deployment. Cerenion’s product architecture also supports expansion beyond a single software metric, spanning the C-Trend station, electrode, amplifier, software library and several quantitative EEG outputs. However, the available employee signal remains broad at 11–50 people, and there is no verified employee-growth series, launch chronology or commercial revenue data. The trajectory therefore indicates sustained product maturation and renewed financing, but not yet a measurable scale-up in market adoption.